论文部分内容阅读
目的:探讨芳香化酶抑制剂和三苯氧胺对70岁以上绝经后期乳腺癌患者新辅助内分泌治疗的疗效。方法:收集96例70岁以上原发性乳腺癌接受新辅助内分泌治疗患者资料,肿瘤性质经病理组织学证实是ER阳性,其中57例接受三苯氧胺资料,39例接受芳香化酶抑制剂治疗。采用免疫组化SP法经行ER、PR和HER2检测。随访时间15~60个月,中位随访时间42个月。结果:芳香化酶抑制剂治疗组完全临床应答率35%,部分应答率为16%,疾病稳定为81%,3年生存率为78.3%;三苯氧胺治疗组完全临床应答率28%,部分应答率11%,疾病稳定为69%,3年生存率为59.3%。差异有统计学意义。结论:芳香化酶抑制剂对70岁以上绝经后乳腺癌患者疗效好于三苯氧胺。
Objective: To investigate the effects of aromatase inhibitors and tamoxifen on neoadjuvant endocrine therapy in patients over 70 years old with postmenopausal breast cancer. Methods: Ninety-six patients with primary breast cancer over 70 years of age receiving neoadjuvant endocrine therapy were enrolled. Tumor characteristics were confirmed by histopathology as ER-positive, of which 57 received tamoxifen and 39 received aromatase inhibitor therapy. Immunohistochemical SP method by ER, PR and HER2 detection. The follow-up time ranged from 15 to 60 months and the median follow-up time was 42 months. Results: The complete clinical response rate, the partial response rate, the partial response rate and the partial response rate were 35%, 16%, 81% and 78.3% respectively in the aromatase inhibitor group. The complete clinical response rate was 28% and the partial response rate 11%, stable disease was 69%, 3-year survival rate was 59.3%. The difference was statistically significant. Conclusions: Aromatase inhibitors are more effective than tamoxifen in postmenopausal women over 70 years of age.